Association of Circulating Antibodies Against Double-Stranded and Single-Stranded DNA with Thyroid Autoantibodies in Graves' Disease and Hashimoto's Thyroiditis Patients[1]

Abstract

The occurrence of antinuclear antibody (ANA), rheumatoid factor (RF), antibodies to double-stranded DNA (anti-dsDNA) and to single-stranded DNA (anti-ssDNA) was investigated in 51 patients with autoimmune thyroid diseases (AITD), and in 25 matched control subjects. In comparison with controls, the prevalence of anti-dsDNA was 74.5 % in AITD patients (p = 0.0001), 82.0 % in 39 hyperthyroid Graves' disease (GD) (p = 0.0001), and 50.0 % in 12 euthyroid Hashimoto's thyroiditis (HT) patients (p = 0.0001). The prevalence of anti-ssDNA was 90.1 % in AITD (94.8 % in GD and 75 % in HT; p = 0.001). The concentration of both anti-dsDNA and anti-ssDNA were higher (p = 0.002) in AITD, in GD (p = 0.001), and in HT (p = 0.01) patients than in controls. Two patients with AITD were identified as positive for ANA. RF was detected in 4 AITD patients. Positive correlation was noted between anti-dsDNA with T4 (p = 0.001), T3 (p = 0.002), thyroid peroxidase antibody (anti-TPO) (p = 0.0001), and TSH (p = 0.001) values but not with thyroglobulin antibody (anti-Tg). Serum anti-ssDNA values were also correlated with T3 (p = 0.0001), TSH (p = 0.003), and anti-TPO (p = 0.0001). However, by using a multiple regression analysis only anti-TPO remained associated with anti-dsDNA and both anti-Tg and anti-TPO with anti-ssDNA values. The predisposition to develop systemic autoimmune disorders is not influenced by thyroid hormones. The elevated prevalence of serum anti-dsDNA and anti-ssDNA in AITD patients points out that we must be aware of the risk for predisposition for the development of other systemic autoimmune diseases.

Key words

Antinuclear antibodies - Graves' disease - Hashimoto's thyroiditis - thyroid autoantibodies

1 Presented in part at the 74th Annual Meeting of the American Thyroid Association, Los Angeles, CA, USA, October 10 - 13, 2002

References

• 1 Armengol M P, Juan M, Lucas-Martin A, Fernández-Figueras M T, Jaraquemada D, Gallart T, Pujol-Borrell R. Demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers.  Am J Pathol. 2001;  159 861-873
• 2 Baethge B A, Levine S N, Wolf R E. Antibodies to nuclear antigens in Graves' disease.  J Clin Endocrinol Metab. 1988;  66 485-488
• 19 Dittmar M, Kahaly G J. Polyglandular autoimmune syndromes: immunogenics and long-term follow-up.  J Clin Endocrinol Metab. 2003;  88 2983-2992
• 3 Gumà M, Salinas I, Roverter J L, Roca J, Valls-Roc M, Juan M, Olivé A. Frequency of antineutrophil citoplasmic antibody in Graves' disease patients treated with methimazole.  J Clin Endocrinol Metab. 2003;  88 2141-2146
• 20 Inamo Y, Harada K. Antinuclear antibody positivity in pediatric patients with autoimmune thyroid disease.  J Rheumatol. 1997;  24 576-578
• 4 Katakura M, Yamada T, Aizawa T, Kunihide H, Yukimura Y, Ishihara M, Takasu N, Maruyama K, Kameko M, Kanai M, Kobayashi I. Presence of antideoxyribonucleic acid antibody in patients with hyperthyroidism of Graves' disease.  J Clin Endocrinol Metab. 1987;  64 405-408
• 5 Kawasaki E, Abiru N, Yano M, Uotani S, Matsumoto K, Matsuo H, Yamasaki H, Yamamoto H, Yamaguchi Y, Akazawa S, Nagataki S. Autoantibodies to glutamic acid decarboxylase in patients with autoimmune thyroid disease: relation to competitive insulin autoantibodies.  J Autoimmun. 1995;  8 633-643
• 6 Kern P, Kron M, Hiesche K. Measurement of antinuclear antibodies: assessment of different test systems.  Clin Diagn Lab Immunol. 2000;  7 72-78
• 7 Loviselli A, Velluzzi F, Pala R, Marcello A, Nurchis P, Mathieu A, Bartalena L, Martina E, Grasso L. Circulating antibodies to DNA-related antigens in patients with autoimmune thyroid disease.  J Reumatol. 1992;  24 576-578
• 8 McDermott M T, West S G, Emlen J W, Kidd G S. Antideoxyribonucleic acid antibodies in Graves' disease.  J Clin Endocrinol Metab. 1990;  71 509-511
• 9 Morita S, Arima T, Matsuda M. Prevalence of nonthyroid specific autoantibodies in autoimmune thyroid diseases.  J Clin Endocrinol Metab. 1995;  80 1203-1206
• 10 Ottesen M, Feldt-Rasmussen U, Andersen J, Hippe E, Schouboe A. Thyroid function and autoimmunity in pernicious anemia before and during cyanocobalamin treatment.  J Endocrinol Invest. 1995;  18 91-97
• 11 Parkim J, Cohen B. An overview of the immune system.  Lancet. 2001;  357 1777-1789
• 12 Perilloux B C, Shetty A K, Leiva L E, Gedalia A. Antinuclear antibody (ANA) and ANA profile tests in children with autoimmune disorders: a retrospective study.  Clin Rheumatol. 2000;  19 200-203
• 13 Petri M, Karlson E W, Cooper D S, Ladenson P W. Autoantibody tests in autoimmune thyroid disease: a case-control study.  J Rheumatol. 1991;  18 1529-1531
• 14 Ruggeri R M, Galetti M, Mandolfino M G, Aragona P, Bartolone S, Giorgianni G, Alesci D, Trimarchi F, Benvenga S. Thyroid hormone autoantibodies in primary Sjogren syndrome and rheumatoid arthritis are more prevalent than autoimmune thyroid disease, becoming progressively more frequent in these diseases.  J Endocrinol Invest. 2002;  25 447-454
• 22 Smeenk R. Detection of antibodies to dsDNA: Current insights into its relevance.  Clin Exp Rheumatol. 2002;  20 294-300
• 21 Sofield R H. Autoimmune thyroid disease in systemic lupus erythematosus and Sjorgren's syndrome.  Clin Exp Rheumatol. 1996;  14 321-330
• 15 Tachi J, Amino M, Iwatani Y, Tamaki H, Mori M, Aozaka M, Tanizawa O, Miyai K. Increase in antideoxyribonucleic acid antibody titer in postpartum aggravation of autoimmune thyroid disease.  J Clin Endocrinol Metab. 1988;  67 1049-1053
• 16 Tektonidou M G, Anapliotou M, Vlachoyiannopoulos P, Moutsopoulos M. Presence of systemic autoimmune disorders in patients with autoimmune thyroid disease.  Ann Rheum Dis. 2004;  63 1159-1161
• 17 Vaidya B, Kendall-Taylor P, Pearce S. Genetics of endocrine disease.  J Clin Endocrinol Metab. 2002;  87 5385-5387
• 18 Weetman A P. Graves' disease.  N Engl J Med. 2000;  343 1236-1248

1 Presented in part at the 74th Annual Meeting of the American Thyroid Association, Los Angeles, CA, USA, October 10 - 13, 2002